Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Amgen stock gained 2.6% to close at $413.08, outperforming the broader market decline. The biotech giant is projected to report EPS of $5.69 (up 0.89% YoY) and revenue of $9.91 billion (up 3.68% YoY). For the full year, consensus estimates project earnings of $22.94 per share and revenue of $38.81 billion. Amgen holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 17.55, trading at a discount to its industry average.